Archives

  • 2018-07
  • 2018-10
  • 2018-11
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2019-12
  • 2020-01
  • 2020-02
  • 2020-03
  • 2020-04
  • 2020-05
  • 2020-06
  • 2020-07
  • 2020-08
  • 2020-09
  • 2020-10
  • 2020-11
  • 2020-12
  • 2021-01
  • 2021-02
  • 2021-03
  • 2021-04
  • 2021-05
  • 2021-06
  • 2021-07
  • 2021-08
  • 2021-09
  • 2021-10
  • 2021-11
  • 2021-12
  • 2022-01
  • 2022-02
  • 2022-03
  • 2022-04
  • 2022-05
  • 2022-06
  • 2022-07
  • 2022-08
  • 2022-09
  • 2022-10
  • 2022-11
  • 2022-12
  • 2023-01
  • 2023-02
  • 2023-03
  • 2023-04
  • 2023-05
  • 2023-06
  • 2023-07
  • 2023-08
  • 2023-09
  • 2023-10
  • 2023-11
  • 2023-12
  • 2024-01
  • 2024-02
  • 2024-03
  • 2024-04
  • Michiel S van der Heijden had full

    2021-09-26

    Michiel S. van der Heijden had full access to all BI-D1870 data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Wang, Sustic, de Oliveira, van den Heuvel, Bernards, van der Heijden. Wang, Sustic, de Oliveira, van de Ven. Wang, Sustic, de Oliveira, Halonen, Lieftink, Beijersbergen, van den Heuvel, Bernards, van der Heijden. Wang, Beijersbergen, van der Heijden. Wang, Sustic, de Oliveira, Lieftink, Halonen, Beijersbergen, van den Heuvel, Bernards, van der Heijden. Halonen, Lieftink, Beijersbergen. van der Heijden, de Oliveira, Beijersbergen. van de Ven. Beijersbergen, Beijersbergen, van der Heijden. None. Michiel S. van der Heijden certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: This work was supported by grants from the Dutch Cancer Society and the Netherlands Organization for Scientific Research to van der Heijden (Veni program) and Cancer Genomics Netherlands; de Oliveira was supported by an EMBO long-term fellowship. None.